BriaCell Therapeutics' Cancer Drug Shows Preliminary Survival, Clinical Benefit In Pretreated Patients

BriaCell Therapeutics Corp BCTX reported preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell's Bria-IMT regimen: patients that have developed resistance to (and failed to respond to) Antibody-Drug Conjugates (ADCs).

Kaplan-Meier analysis showed median overall survival (OS) that was up to twice that reported in the literature, with some patients recording survival of over a year.

The disease control rate of 40% was observed in evaluable patients, further indicating clinical benefit.

Progression-free survival (PFS) was similar or better than that of the patient's prior therapy in 40% of patients, highlighting the clinical benefit and tolerability of the Bria-IMT regimen.

17 of 23 patients remain alive today, suggesting the efficacy, tolerability, and survival benefit of BriaCell's Bria-IMT regimen. The data will continue to mature as patients remain on the study.

All patients received BriaCell's therapy with no toxicity-related discontinuations.

There were no cases of Interstitial Lung Disease with Bria-IMT – a well-documented serious side effect of ADCs. 

Price Action: BCTX shares are up 4.31% at $4.11 on the last check Wednesday.